GlassScriptPhysician profile
Julia Roberts
NPI 1528439783
$5,423.34
in general payments reported to CMS, 2019-2025
28 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $969 · 2022: $1,040 · 2023: $963 · 2024: $1,049 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,414.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $653.16 | 2021-2025 | Evenity, Krystexxa |
| Teva Pharmaceuticals USA, INC. | $535.50 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.15 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $422.19 | 2022-2023 | Xarelto |
| Abbvie INC. | $378.38 | 2021-2024 | |
| Novo Nordisk INC | $327.38 | 2021-2025 | Wegovy |
| Axonics, INC. | $279.23 | 2023-2024 | Axonics |
| Axsome Therapeutics, INC. | $269.66 | 2024-2025 | Symbravo, Sunosi |
| Madrigal Pharmaceuticals | $254.23 | 2025 | Rezdiffra |
| Ars Pharmaceuticals Operations, INC. | $126.27 | 2025 | Neffy |
| Neurocrine Biosciences, INC. | $125.46 | 2023 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $125.38 | 2024 | Voquezna |
| Forte Bio-Pharma LLC | $125.01 | 2025 | Prolate, Tanlor, Nalocet |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.67 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $122.25 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $122.15 | 2025 | |
| Boston Scientific Corporation | $121.23 | 2023 | Watchman |
| Nevro Corp. | $120.90 | 2022-2024 | Senza |
| Genentech USA, INC. | $95.36 | 2021 | |
| Gilead Sciences, INC. | $94.95 | 2023-2025 | Trodelvy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $88.77 | 2022 | |
| Jazz Pharmaceuticals INC. | $88.20 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $84.88 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.87 | 2025 | |
| Paratek Pharmaceuticals, INC. | $79.02 | 2025 | Nuzyra |
| Corium, LLC | $63.20 | 2023 | Azstarys |
| Biohaven Pharmaceuticals, INC. | $21.93 | 2021 | |
| Galderma Laboratories, L.P. | $12.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.